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BACKGROUND: Loss of HLA class I is important in ovarian cancer prognosis but its role as a prognostic indicator in relation to therapy
remains unproven. We studied the prognostic potential of this antigen and its significance in relation to platinum therapy.
METHODS: A total of 157 primary ovarian cancers were assessed for HLA class I immunohistochemically and linked to a
comprehensive database of clinicopathological variables, treatment details, and platinum sensitivity.
RESULTS: Tumours expressing high levels of HLA class I had significantly improved survival (P¼0.044). There was a 19-month
difference in the median overall survival between tumours with high and low antigen expression. HLA class I antigen expression,
stage, and platinum sensitivity were independently predictive of prognosis on multivariate analysis. HLA class I antigen was shown to
be expressed at higher levels in patients with good overall survival in platinum-resistant patients (P¼0.042). HLA class I significantly
correlated with overall survival on multivariate analyses (P¼0.034).
CONCLUSION: Low-level HLA class I expression is an independent prognostic indicator of poor clinical outcome in ovarian cancer.
The survival advantage of patients with platinum-resistant tumours expressing high levels of HLA class I suggests that immunotherapy
may be of use in these ovarian cancers resistant to standard chemotherapy.
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In the UK, ovarian cancer is the most common gynaecological
cancer and is the fourth most common after cancers of the breast,
large bowel, and lung, representing approximately 5% of all
cancers in women. The 5-year survival rate has only improved
from 30% in the period from 1986–1990 to 38% in 1996–1999
(Quinn, 2001).
Some advances have been made in the development of novel
chemotherapeutic agents; however, their impact on cancer-related
mortality is limited. The current standard treatment of ovarian
cancer is primary surgery followed by platinum-based chemo-
therapy. Regimens that contained platinum salt±taxenes have
been established as the standard chemotherapy in ovarian cancer
through a number of clinical studies including GOG111, OV10,
ICON3, and GOG132 (McGuire et al, 1996; Muggia et al, 2000;
Piccart et al, 2000; ICON_Group, 2002). Multiple agents in a
sequential approach for more prolonged treatment (GOG182-
ICON5) failed to show a benefit over standard chemotherapy of a
platinum salt and a taxene combination for six cycles (Bookman,
2006). The results of adding novel targeting agents such as the
VEGF-targeting monoclonal antibody bevacizumab are eagerly
awaited (ICON7). However, only palliative treatment is available to
patients with tumours that are resistant to platinum chemother-
apy. The patients have a median survival of 6 months from the
time of documented resistance (Markman et al, 2004). There is an
urgent need for novel approaches for these tumours that are
resistant to platinum chemotherapy.
Although clinicopathological prognostic factors like tumour
stage, grade, age, residual disease after surgical debulking, and
response to chemotherapy predict prognosis in ovarian cancer;
there is large individual variation in prognosis of apparently
similar tumours when using these standard clinical variables
(Rubin et al, 1999). This discrepancy may be accounted for by
variations at the molecular level, or the interaction of certain
factors like the immune system in the disease process. An
important mechanism by which the immune system eliminates
cancer cells is through a cytotoxic T lymphocyte (CTL)-based
response to abnormal peptide presented in conjunction with HLA
class I antigen on tumour cells (Seliger et al, 2000). Through a series
of sequential steps, HLA class I antigen-tumour associated antigen-
derived peptide complexes are formed, transported to the cell
membrane, and presented to CTL. This process leads to the formation
of complexes made of the peptide with both component units of the
HLA molecule (b2-microglobulin (b2m) and class I heavy chain).
This complex travels to the cell membrane where peptides are
presented to CTL (Momburg and Tan, 2002; Bouvier, 2003).
Previous work in breast and colorectal cancers has supported
this theory, with loss of HLA class I expression shown as an
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2006). In ovarian cancer, T-cell infiltration is associated with better
survival, which suggests a role for the immune system in its
prognosis (Zhang et al, 2003). There is evidence from our group
and others that HLA class I is important in ovarian cancer
prognosis (Rolland et al, 2007; Han et al, 2008) but this prognostic
function is not known in the context of platinum sensitivity. The
purpose of this study was to study the prognostic potential of HLA
class I antigen in a group of homogenously treated ovarian cancer
patients with platinum chemotherapy and correlate that with their
sensitivity to chemotherapy.
PATIENTS AND METHODS
Patients
This study includes 157 patients with primary ovarian cancer
treated at Nottingham University Hospitals (NUH) from the year
2000–2007. The haematoxylin/eosin (H&E) sections of these
tumours were reviewed by a gynae-pathologist (SD) masked to
the clinical data and pathological diagnosis. Tumours were typed
and graded with representative areas marked to be cored for the
arrayed blocks. Clinicopathological variables for this cohort were
recorded, including age at diagnosis, FIGO stage, extent of
cytoreduction, tumour grade and histological subtype. Details of
adjuvant treatment, disease-free survival (DFS) and overall
survival were documented for all patients. Survival was calculated
from the operation date until 30 June 2008 when any remaining
survivors were censored. Median follow-up was 36 months. During
the study period, all patients were treated by the current standard
chemotherapy with either single agent carboplatin in 65 patients
(41.4%) or platinum-based combination chemotherapy in 89
patients (56.7%). Of them, 79 were given carboplatin and
paclitaxel. CAP was used in four patients (2.5%). Three patients
(1.9%) were treated in ICON5 trial using paclitaxel, carboplatin
with gemcitabine or topotecan. Another three patients were treated
according to the SCOTROC trial protocol by carboplatin,
docetaxel±topotecan. Platinum-resistant cases were defined as
patients who progressed with first-line platinum chemotherapy
during treatment or relapsed within 6 months after treatment.
Specimens
Tissue microarrays (TMA) were constructed from prechemother-
apy paraffin-embedded tumour samples. For each tumour, H&E-
stained slides were first used to locate representative areas of
viable tumour tissue. Needle core-biopsies (0.6mm) from the
corresponding areas on the paraffin-embedded tumour blocks
were then placed at pre-specified coordinates in recipient paraffin
array blocks using a manual tissue arrayer (Beecher Instruments,
Sun Prarie, WI, USA). Array blocks were constructed with 89–100
cores in each recipient block. Three copies of the array were
assembled using different points from the representative tumour
areas. Fresh 4mm sections were obtained from each TMA block
and placed on coated glass slides to allow the immunohisto-
chemical procedures to be performed, preserving maximum tissue
antigenicity.
Immunohistochemistry
Immunohistochemical staining for HLA class I antigen expression
was performed using a routine avidin/biotin peroxidase method.
Tissue array sections were first deparaffinised with xylene,
rehydrated through graded alcohol, and immersed in methanol
containing 0.3% hydrogen peroxide for 20min to block endo-
genous peroxidase activity. To retrieve antigenicity, sections were
immersed in 500ml (pH 6.0) citrate buffer and heated for 10min
in an 800W microwave at high power, followed by 10min at low
power. Endogenous avidin/biotin binding was blocked using an
avidin/biotin blocking kit (Vector Labs, Peterborough, UK). To
block non-specific binding of the primary antibody, all sections
were then treated with 100ml of normal swine serum (NSS) diluted
1:20 in Tris-buffered saline (TBS) for 15min.
Test sections were incubated with 100ml of mouse anti-human
monoclonal antibody to HLA class I heavy chain (HC-10; a gift
from Prof H Ploegh, Harvard Medical School) and to the HLA class
I b2m subunit (A0072; Dako, Ely, UK) at dilutions of 1:1500 and
1:2000 respectively. Dilutions were made in NSS/TBS, and left to
incubate on the sections for 60min at room temperature. Positive
control tissue comprised whole sections of tonsil. The primary
antibody was omitted from the negative control, which was left
incubated in NSS/TBS.
After washing with TBS, all sections were incubated with 100ml
of biotinylated goat anti-mouse/rabbit immunoglobulin (Dako)
diluted 1:100 in NSS/TBS for 30min. Sections were washed again
in TBS and next incubated with 100ml of pre-formed streptavidin–
biotin/horseradish peroxidase complex (Dako) for 60min at room
temperature. Subsequently, visualisation of HLA class I expression
was achieved using 3,30-diaminobenzidine tetrahydrochloride
(Dako). Finally, sections were lightly counterstained with haema-
toxylin (Sigma, Gillingham, UK), dehydrated in alcohol, cleared in
xylene, and mounted with distyrene, plasticizer and xylene (DPX;
BDH, Poole, UK).
Evaluation of HLA class I
To stain for the widest range of HLA class I heavy chains with a
single antibody, we selected the mouse anti-human monoclonal
antibody to HLA class I heavy chain. This antibody was raised to
denatured HLA class I heavy chain freed from the b2m light-chain
element of denatured native HLA class I antigen and preferentially
recognises HLA-B and HLA-C on formalin-fixed, paraffin-
embedded tissue (Stam et al, 1986). HLA class I antigens require
the presence of b2m to function, and co-staining these tumours for
b2m using a commercial polyclonal rabbit anti-human antibody
(A0072; Dako) allowed the generation of HLA heavy-chain/b2m
phenotypes.
We used three different copies of the TMA providing three
samples from different areas of the tumour in each case. Following
initial review of the staining characteristics, we scored TMAs using
a semi-quantitative ‘H-score’ system by two experienced indepen-
dent observers (MS and AM). The scoring was performed in a
coded manner with observers masked to the clinical and
pathological parameters of the case. To use both the staining
intensity (graded 0, absent; 1, weak; 2, moderate; 3, strong) and
distribution (percent cells staining) in the assessment of each core,
we calculated an intensity score (percent cells staining intensity
of staining). A mean value was calculated for the three cores from
each tumour to record heterogeneously stained HLA components
accurately. In case of disagreement between the two assessors, and
to reach a consensus on difficult cases, a third (SD) assessor was
consulted. Slides were captured digitally using NanoZoomer
scanner (Hamamatsu Photonics, Welwyn Garden City, UK), using
a maximum magnification of  200.
The cut-off value for positivity for either antigen was an H score
of 410. Cell-surface expression of HLA requires the expression
of both heavy chain and b2m. The HLA heavy chainþ/
b2mþphenotype was defined to be HLA class I positive, and
any deviation from that was considered HLA down-regulation.
Statistical analysis
Statistical analysis of the study data was performed using the SPSS
package (version 15 for Windows; SPSS Inc, Chicago, IL, USA).
Pearson’s w
2-tests were used to determine the significance
of associations between categorical variables. Overall survival
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scalculations included all patients who died during the follow-up.
Survival rates were calculated using the Kaplan–Meier method;
differences between groups were tested using the log-rank test.
Events for DFS and overall survival were defined as follows: time of
disease relapse or death (for DFS) and time of death (for overall
survival) respectively. The Cox proportional-hazards model was
used for multivariate analysis to determine the relative risk and
independent significance of individual factors. In all cases P-values
o0.05 were considered as statistically significant.
Ethical approval to carry out the study was granted by the
Derbyshire Local Research Ethics Committee.
RESULTS
Clinicopathological characteristics
The median age at diagnosis was 61 years (range 33–87 years). The
majority of cases were at advanced stages. 59% of the patients
had stage 3 and 4 disease (n¼92). A total of 114 patients (72.6%)
had grade 3 tumours, 23 (14.6%) had grade 2, and 20 (12.7%) had
well-differentiated tumours. Serous and endometrioid were the
commonest histological subtypes in this cohort. More than 44%
of cases (n¼69) were deemed to be suboptimally debulked after
initial surgery. Carboplatin alone was used in 41.4% (65 out of 157)
of patients whereas combined platinum regimens were given in
56.7% (89 out of 157). Three patients (1.9%) refused chemother-
apy. Table 1 shows the full clinicopathological characteristics of
the patient cohort.
HLA class I staining
Staining was seen predominantly within the cell membrane and
some cytoplasmic staining. There was no staining in negative
controls. The use of H score allowed the heterogeneity of HLA class
I expression to be taken into account. The mean H score was
calculated by obtaining three cores from each tumour. The cut-off
value for positivity for both HLA class I antigens was an H score of
410 and this cut-off value was previously found to separate high
expression from low expression effectively (Rolland et al, 2007).
59% of tumours were positive for b2m and 63% were positive for
HC10. Overall, 52% were HC10þ/b2mþ (n¼82) whereas 46%
were negative (n¼72). Three cores (1.9%) were unscorable due to
insufficient tumour tissue left after the staining procedure. Figure 1
shows positively and negatively stained cores using the HC10 and
b2m antibodies.
Correlation of HLA class I expression with patient
characteristics including survival
In univariate analysis, using the w
2-test, no significant relationship
between HLA class I expression and the standard clinical and
pathological variables was detected except in clear-cell carcinoma
(CCC) and in relation to patients’ age. The level of expression was
significantly less in CCC subtype (P¼0.049), and was lower in
older (460 years) patients (P¼0.035; Table 2).
Correlations between HLA class I expression and patient
survival were also assessed using Kaplan–Meier survival curves
and log-rank testing (Figure 2). There was a statistically significant
difference in the overall survival between patients with high and
low HLA class I expression, with high expression predicting an
improved outcome (log rank¼4.03; P¼0.045). The median
overall survival was 56 and 37 months for high and low antigen
expression respectively. This equates to a 19-month difference in
survival between the two groups. To assess whether HLA class I
status was an independent marker of prognosis, the relative
influence of its expression and other known standard clinico-
pathological prognostic variables were included in a multivariate
analysis. Factors shown to predict prognosis independently were
FIGO stage, platinum sensitivity, and HLA class I expression.
These factors were included in a Cox multivariate regression
analysis. As shown in Table 3A, HLA class I was seen to retain its
power to predict an improved prognosis in the study population,
independent of other prognostic factors (HR¼0.524, 95%
CI¼0.291–0.946; P¼0.032).
Although progression-free survival was also worse in patients
with low expression compared to patients with high expression
(19 vs 36 months), it did not reach statistical significance
(log rank¼0.58, P¼0.446).
Table 1 Patients’ clinicopathological characteristics and HLA-I frequencies
in all patients (A), and in platinum resistant patients (B)
Characteristics Frequencies Percentages
(A)
Pathology
Serous 88 56.1
Mucinous 12 7.6
Endometrioid 33 21
Clear cell 21 13.4
Other 3 1.9
Grade
1 20 12.7
2 23 14.6
3 114 72.6
Debulking surgery
Optimal 88 56.1
Suboptimal 69 43.9
Stage
IC 44 28
II 21 13.4
III 71 45.2
IV 21 13.4
Chemotherapy
Carboplatin monotherapy 65 41.4
Carboplatin combination 89 56.6
No chemotherapy 3 1.9
Platinum sensitivity
Sensitive 104 66.2
Resistant 50 31.8
Unknown 3 1.9
HLA class I
Positive 82 58.6
Negative 72 45.9
Unknown 3 1.9
hC-10
Positive 99 63.1
Negative 56 35.7
Unknown 2 1.3
b2m
Positive 92 58.6
Negative 63 40.1
Unknown 2 1.3
Relapse status
Relapsed 75 47.8
Relapse free 75 47.8
Unknown 7 4.5
Survival status
Living 103 65.6
Dead 54 34.4
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sThis group of patients was stratified according to their platinum
sensitivity. For both platinum-sensitive and -resistant groups, HLA
class I-positive group tend to do better than HLA class I-negative
group in terms of overall survival but this was only statistically
significant in the platinum-resistant group (log rank¼4.14;
P¼0.0419) (Figure 3). The median survival in the platinum-
resistant HLA-positive and -negative groups was 24 and 18 months
respectively. In the platinum-resistant group, HLA class I was the
only marker that significantly correlated with overall survival
(P¼0.042). When HLA class I was included in a multivariate
model that included stage, extent of debulking surgery, and grade,
HLA class 1 remained statistically significant (HR¼0.034, 95%
CI¼0.202–0.932; P¼0.034; Table 3B).
Other clinicopathological variables that were associated with
favourable overall survival in this cohort of patients were lower
tumour stage (Po0.001) and grade (P¼0.04), optimal debulking
(P¼0.005), and platinum sensitivity (Po0.001).
Sixty-five patients were found to have measurable disease before
chemotherapy; three of whom were not assessed for response. Of
the 62 patients remaining, the response rate (CR and PR) to single
agent carboplatin was 87.5% compared to 78.9% in the combina-
tion chemotherapy group (P¼0.412). Also, there was no
statistically significant difference in chemoresponse when patients
were stratified by their expression of HLA class I (P¼0.522).
DISCUSSION
There is increasing evidence from animal studies that the immune
system acts as an intrinsic tumour suppressor and prevents
tumour growth. However, the inherent variation in tumour cell
phenotype associated with either microsatellite instability or
chromosomal instability may facilitate the avoidance of immune
attack in a process known as ‘immune-editing’. Tumour cells
which lose antigen, HLA molecules, or produce immune suppres-
sive cytokines may thus have a selective advantage, and markers of
this process can function as prognostic indicators (Dunn et al,
2002).
The loss of HLA class I antigens is one of the escape mechanisms
found most frequently in experimental and spontaneous tumours.
Tumour cells can use multiple mechanisms to, partially or
completely, down-regulate the expression of HLA class I antigens.
A variety of altered HLA phenotypes have been defined in human
tumours, including HLA total loss, HLA haplotype loss, HLA-
specific locus down-regulation, HLA allelic losses, and a combina-
tion of these phenotypes (Garrido et al, 1997; Garrido and Algarra,
2001). HLA genes control the synthesis of molecules that are in
many ways the centre of the immune function mediated by
T lymphocytes and natural killer (NK) cells. An increasing
proportion of tumours have been found to show such alterations
(Garrido et al, 1993). Total or selective losses of HLA class I
antigens have been reported in different human tumour types
(Garrido et al, 1997; Garrido and Algarra, 2001).
In our study, we reported the down-regulation of HLA class I
antigen in ovarian cancer which in concordance with other studies
(Vitale et al, 2005; Han et al, 2008) appears to be a common event.
Our findings show that HLA class I heavy chain was positive
in 63% and b2m positive in 58% of patients. Intact HLA
(HCþ/b2mþ) phenotype occurred in 52% of the cases. These
figures are similar to those of Vitale et al who also showed that
HLA heavy chain was positive in 62.7% of their cases. However,
our figures were slightly different from the results of the study
carried out by Han et al (2008) who showed that HLA-HC and b2m
were positive in 70.7 and 63.3% respectively. Multiple reasons
might contribute to the differences in frequency of HLA class I in
different studies. Some of them are related to the technique of
immunohistochemistry such as the characteristics of monoclonal
antibody used and the subjective evaluation of the staining. Other
factors might be related to the difference of the patients’
population in each study.
Our findings show that intact HLA phenotype confers better
prognosis in terms of overall survival. This coincides with
previously published results from other groups (Han et al, 2008)
as well as from our group on a different cohort of patients (Rolland
et al, 2007). However, Vitale et al (2005) did not show a survival
advantage for HLA class I in ovarian cancer. This might be due to
their methodology of immunostaining for HLA class I as they
stained only using HC10 antibody which stains only HLA class I
heavy chains (HLA-HC) but they did not stain for b2m which is an
essential molecule for proper function of HLA class I. Overall
survival was significantly worse in patients with low expression of
HLA class I. Although progression-free survival was also worse in
patients within this group, it did not reach statistical significance
Table 1 (Continued)
Characteristics Frequencies Percentages
(B)
Pathology
Serous 38 74.5
Mucinous 1 2
Endometrioid 6 11.8
Clear cell 4 7.8
Other 2 3.8
Grade
1 3 5.9
2 5 9.8
3 43 84.3
Debulking surgery
Optimal 16 31.4
Suboptimal 35 68.6
Stage
IC 2 3.9
II 4 7.8
III 30 58.8
IV 15 29.4
Chemotherapy
Carboplatin monotherapy 14 27.5
Carboplatin combination 37 72.5
No chemotherapy 0 0
HLA class I
Positive 22 43.1
Negative 27 52.9
Unknown 2 3.9
HC-10
Positive 29 56.9
Negative 20 39.2
Unknown 2 3.9
b2m
Positive 27 52.9
Negative 23 45.1
Unknown 1 2
Relapse status
Relapsed 49 96.1
Relapse free 0 0
Unknown 2 3.9
Survival status
Living 7 13.7
Dead 44 86.3
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several factors such as second-line chemotherapy. In addition, we
noticed a difference in survival, which was only significant in the
platinum-resistant patients. This is probably because platinum-
sensitive patients usually have a higher response to second-line
chemotherapy compared to platinum-resistant cases whose re-
sponse to second-line chemotherapy is lower even with non-
platinum chemotherapy (Main et al, 2006). Thus, these patients may
have to rely on other mechanisms to battle their disease. This was
shown in our series by HLA class I expression which is important
for the immune system to recognise and attack cancer cells.
The previous work from our group included patients treated
since 1982 and a considerable number of them were not treated by
the current standard of treatment with platinum-based chemother-
apy. The current study included a homogenous group of patients
treated at NUH since 2000 in a uniform manner with the current
standard chemotherapy. Both studies showed that HLA class I
down-regulation is poor prognostic factor independent of other
clinicopathological criteria. Although there was a difference in
patient cohort and the treatment received, we were able to
reproduce similar findings in a more representative cohort that
reflects current practice of ovarian cancer management.
Because platinum-based chemotherapy was the only treatment
received by the patients included in this study, we had the
opportunity to correlate our findings in relation to platinum
sensitivity which is a major determinant of prognosis in ovarian
cancer. This has not been reported before from any other group.
From our data, patients with platinum-sensitive tumours had
significantly better survival compared to platinum-resistant
tumours with a median survival of 74 and 21 months in the two
groups respectively (log rank¼68.24; Po0.001). There is currently
no effective treatment for patients with platinum-resistant disease.
In the Health Technology Assessment of three drugs used in
second-line treatment of ovarian cancer, it has been shown that in
patients with platinum-resistant disease there was a low prob-
ability of response to treatment with pegylated liposomal
doxorubicin hydrochloride, topotecan, or paclitaxel. Response
rates varied from 6.7 to 13.3%. Likewise, there was little difference
between the three comparators in relation to overall survival, with
median survival times varying from 36.7 to 54.3 weeks (Main et al,
2006). This underscores the need for novel therapeutic approaches
in such a group of patients.
In our study, there were no significant difference about type of
treatment (single or combination) and number of cycles received
between HLA class I-positive and -negative cases. We found that
HLA class I down-regulation is associated with poor overall
survival in platinum-sensitive and -resistant groups of patients but
this reached statistical significance only in the resistant group.
This suggests that in the absence of effective chemotherapy for the
platinum-resistant group, the immune system might be important
in the prognosis of that particular group of patients and hence
should be a target for cancer vaccines.
Figure 1 Immunohistochemical staining of tissue microarray cores with b2m and hC10 antibodies. (A and B) Cores from tumour showing negative
(A) and positive (B) b2m staining. (C and D) Cores of tumour showing negative (C) and positive (D) hC10 staining. Original magnification  100;
insets  400.
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sAlternatively, a role for NK cells in the immune-mediated
response to a tumour could be suggested in case of down-
regulation of HLA class I. When HLA class I antigen expression is
lost, killer cell inhibitory receptors on the surface of NK cells
(which produce an inhibitory signal when bound to HLA class I
antigen) no longer function. This could result in increase in NK
cell activity and might help to compensate for the decrease in
T-cell killing associated with down-regulation of HLA class I
(Ljunggren and Karre, 1990). However this theoretical advantage
of NK cells was not supported by our data. However, it was
previously reported that a broad spectrum of tumours often up-
regulates the expression of non-classical HLA class I, like HLA-G
which dampens the NK-cell responses by engaging inhibitory
receptors ILT-2 and KIR2DL4 (Rouas-Freiss et al, 2005; Urosevic
and Dummer, 2008). This was also seen in ovarian cancer where
HLA-G was not only expressed in high-grade serous carcinoma but
also conferred tumour cells aggressiveness (Seliger et al, 2003).
These findings suggest that HLA-G expression represents a
mechanism of resistance of NK cells in a manner that parallels
its mechanism to protect against NK-mediated foetal tissue
rejection in the placenta (Hunt et al, 2006).
Clear-cell carcinoma represents a special subtype of ovarian
cancer with known bad prognosis and resistance to platinum
HLA class I
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Figure 2 Association of HLA-I expression with overall survival time in
154 patients with primary ovarian cancer. Median survival time was 37
months for patients with negative HLA-I expression (HLA-I negative,
n¼72) compared with 56 months for patients with positive HLA-I
expression (HLA class I positive, n¼82). The difference was significant in
the log-rank test (P¼0.0448).
Table 2 Tumour expression of HLA-I vs clinicopathological features
Variables HLA-I +ve HLA-I  ve P-value
Age groups
460 Years 62 38 0.035
p60 Years 45 55
Pathology
Serous 51 34 0.078
Mucinous 6 6
Endometrioid 18 15
Clear cell 7 14
Other 3
CCC vs others
CCC 7 14 0.049
Other types 75 58
Stage
I and II 35 30 0.899
III and IV 47 42
Grade
1 and 2 28 15 0.264
36 4 4 8
Debulking surgery
Optimal 49 39 0.484
Suboptimal 33 33
Platinum sensitivity
Sensitive 59 44 0.189
Resistant 22 26
Abbreviation: CCC¼clear-cell carcinoma. The association of HLA-I with CCC is also
shown compared to the other pathological types combined. Significant P-values are
shown in bold.
Table 3 Multivariate analysis of the effects of investigated parameters on
overall survival using a Cox proportional-hazard regression model in all
patients (A) and the platinum-resistant group (B)
95% CI for HR
Variables HR Lower Upper P-value
(A)
Grade
31
1+2 0.997 0.478 2.080 0.994
Stage
I+II 1
II+IV 2.787 1.116 6.963 0.028
Debulking surgery
Suboptimal 1
Optimal 0.968 0.520 1.804 0.920
Platinum sensitivity
Sensitive 1
Resistant 6.129 3.055 12.297 o0.001
HLA class I
Negative 1
Positive 0.524 0.291 0.946 0.032
(B)
Grade
31
1+2 0.659 0.273 1.590 0.323
Stage
I+II 1
II+IV 1.094 .357 3.348 0.875
Debulking surgery
Suboptimal 1
Optimal 0.792 0.381 1.646 0.531
HLA class I
Negative 1
Positive 0.440 0.206 0.938 0.034
The prognostic impact of HLA class I was adjusted for well-established clinical
prognostic factors including histological grade, FIGO stage, debulking surgery and
platinum sensitivity. Significant P-values are shown in bold. Platinum sensitivity is not
included in B as the data included the platinum-resistant patients only.
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schemotherapy (Sugiyama et al, 2000). We found a significant
correlation between HLA class I down-regulation and clear-cell
subtype compared to other histological subtypes. As expected, no
significant difference in survival was noted in this group when
compared to serous carcinoma. This is because cases of CCC are
diagnosed, in general, as early stage. The outcome of such patients
does not differ from that of serous adenocarcinoma.
Our report shows that down-regulation of HLA class I is a poor
prognostic factor in ovarian cancer independent from other
clinicopathological markers. The HLA class I-negative status
represents a class of patients who do worse irrespective of current
therapy. The survival advantage of patients with platinum-resistant
tumours expressing high levels of HLA class I suggests that
immunotherapy might be important as a therapeutic option in the
management of these patients.
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